中文名称: | 盐酸小檗碱 | ||||
---|---|---|---|---|---|
英文名称: | Berberine hydrochloride | ||||
别名: | 盐酸黄连素 9,10-dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium chloride | ||||
CAS No: | 633-65-8 | 分子式: | C20H18ClNO4 | 分子量: | 371.81 |
CAS No: | 633-65-8 | ||||
分子式: | C20H18ClNO4 | ||||
分子量: | 371.81 | ||||
MDL: | MFCD00011939 | EINEC: | 211-195-9 | ||
EINEC: | 211-195-9 |
基本信息
产品编号: |
B10055 |
||||
产品名称: |
Berberine hydrochloride |
||||
CAS: |
633-65-8 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
||||
分子式: |
溶于液体 |
-80℃ |
两年 |
||
分子量 |
371.81 |
-20℃ |
一个月 |
||
化学名: |
9,10-dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium chloride |
||||
Solubility (25°C): |
|||||
体外:
|
DMSO |
25mg/mL (67.23mM) |
|||
Ethanol |
Insoluble |
||||
Water |
Insoluble |
||||
体内(现配现用): |
1.请依序添加每种溶剂:0.5% CMC-Na/saline water Solubility: 11mg/mL (29.59mM); Suspended solution; Need ultrasonic |
||||
2.请依序添加每种溶剂:PBS Solubility: 10mg/mL (26.90mM); Suspended solution; Need ultrasonic |
|||||
3.请依序添加每种溶剂:10% DMSO→40% PEG300→5% Tween-80→45% saline Solubility: ≥ 1.25mg/mL (3.36mM); Clear solution |
|||||
此⽅案可获得 ≥ 1.25mg/mL (3.36mM,饱和度未知) 的澄清溶液。以 1mL ⼯作液为例,取 100μL 12.5mg/mL 的澄清 DMSO 储备液加到 400μL PEG300 中,混合均匀;向上述体系中加⼊ 50μL Tween-80,混合均匀;然后继续加⼊ 450μL ⽣理盐⽔定容⾄ 1mL。 |
|||||
4.请依序添加每种溶剂:10% DMSO→90% (20% SBE-β-CD in saline) Solubility: ≥ 1.25mg/mL (3.36mM); Clear solution |
|||||
此⽅案可获得 ≥ 1.25mg/mL (3.36mM,饱和度未知) 的澄清溶液。 以 1mL ⼯作液为例,取 100μL 12.5mg/mL 的澄清 DMSO 储备液加到 900μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中,混合均匀。 |
|||||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
2.6895mL |
13.4477mL |
26.8955mL |
5mM |
0.5379mL |
2.6895mL |
5.3791mL |
10mM |
0.2690mL |
1.3448mL |
2.6895mL |
50mM |
0.0538mL |
0.2690mL |
0.5379mL |
生物活性
产品描述 |
一种具有弱抗菌特性的生物碱。 |
|||||
靶点 |
Caspase-3 |
Caspase-8 |
PARP |
cytochrome c |
cIAP1 |
|
体外研究 |
Berberine (1.25-160μM; 72 hours) has potential inhibitory effects on the proliferation of four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29. Berberine (1.25-160μM; 24-72 hours) induces a time- and dose-dependent inhibition of LoVo cell growth. LoVo cells are exposure to Berberine (10-80μM) for 24 h. Cell cycle analysis of 40μM Berberine-treated LoVo cells by flow cytometry shows accumulation of cells in the G2/M phase. Berberine (10-80μM) suppresses cyclin B1, cdc2 and cdc25c protein expression after 24 h, especially at the dose of 80.0μM Cell Proliferation Assay |
|||||
Cell Line: |
Four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29 |
|||||
Concentration: |
1.25, 2.5, 5, 10, 20, 40, 80, and 160μM |
|||||
Incubation Time: |
72 hours |
|||||
Result: |
Inhibited the proliferation of four cell lines. The IC50 ranged from 40.8±4.1μM (LoVo) to 98.6±2.9μM (HCT116). |
|||||
Cell Proliferation Assay |
||||||
Cell Line: |
Colorectal carcinoma cell lines LoVo |
|||||
Concentration: |
1.25, 2.5, 5, 10, 20, 40, 80, and 160μM |
|||||
Incubation Time: |
24, 48, 72 hours |
|||||
Result: |
Induced a time- and dose-dependent inhibition of cell growth. By 72 h, 160.0μM induced 71.1±1.9 % growth inhibitions in LoVo cells. |
|||||
Cell Cycle Analysis |
||||||
Cell Line: |
LoVo cells |
|||||
Concentration: |
0, 10, 20, 40, or 80μM |
|||||
Incubation Time: |
24 hours |
|||||
Result: |
Exposure to 40.0μM induced G2/M-phase cell cycle arrest, an increase in the G2/M-phase population and a progressive decline in the G1 population. |
|||||
Western Blot Analysis |
||||||
Cell Line: |
LoVo cells |
|||||
Concentration: |
10, 20, 40, or 80μM |
|||||
Incubation Time: |
24 hours |
|||||
Result: |
Suppressed cyclin B1, cdc2 and cdc25c protein expression. |
|||||
体内研究 |
Berberine (10, 30, or 50mg/kg/day; gastrointestinal gavage; for 10 consecutive days) inhibits the growth of human colorectal adenocarcinoma in vivo. Berberine at doses of 30 and 50mg/kg/day taken by gastrointestinal gavage shows inhibitory rates of 33.1% and 45.3% on the human colorectal adenocarcinoma xenograft growth in nude mice |
|||||
Animal Model: |
5-week-old BALB/c nu/nu mice with human colorectal adenocarcinoma LoVo xenografts |
|||||
Dosage: |
10, 30, or 50mg/kg/day |
|||||
Administration: |
Gastrointestinal gavage; for 10 consecutive days |
|||||
Result: |
Showed inhibitory rates of 33.1 % and 45.3 % at doses of 30 and 50mg/kg/day. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )